Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Receives Consensus Rating of “Hold” from Brokerages

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) has received an average rating of “Hold” from the ten research firms that are currently covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, six have issued a hold rating and three have assigned a buy rating to the company. The average 12-month price target among brokers that have issued ratings on the stock in the last year is $9.33.

A number of equities research analysts have recently issued reports on FULC shares. Royal Bank of Canada reissued a “sector perform” rating and issued a $4.00 price target on shares of Fulcrum Therapeutics in a report on Thursday, November 14th. Leerink Partnrs downgraded shares of Fulcrum Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Thursday, September 12th. Bank of America downgraded shares of Fulcrum Therapeutics from a “neutral” rating to an “underperform” rating and lowered their target price for the company from $10.00 to $2.00 in a research note on Thursday, September 12th. Stifel Nicolaus downgraded shares of Fulcrum Therapeutics from a “buy” rating to a “hold” rating and lowered their target price for the company from $22.00 to $3.00 in a research note on Thursday, September 12th. Finally, Leerink Partners reaffirmed a “market perform” rating and issued a $4.00 target price on shares of Fulcrum Therapeutics in a research note on Thursday, September 12th.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of FULC. National Bank of Canada FI grew its position in Fulcrum Therapeutics by 869.6% during the second quarter. National Bank of Canada FI now owns 4,460 shares of the company’s stock valued at $28,000 after acquiring an additional 4,000 shares during the last quarter. China Universal Asset Management Co. Ltd. grew its holdings in shares of Fulcrum Therapeutics by 64.4% in the third quarter. China Universal Asset Management Co. Ltd. now owns 12,002 shares of the company’s stock worth $43,000 after purchasing an additional 4,701 shares during the last quarter. Walleye Capital LLC bought a new position in shares of Fulcrum Therapeutics in the third quarter worth approximately $59,000. Intech Investment Management LLC bought a new position in shares of Fulcrum Therapeutics in the third quarter worth approximately $62,000. Finally, Profund Advisors LLC bought a new position in shares of Fulcrum Therapeutics in the second quarter worth approximately $68,000. 89.83% of the stock is currently owned by institutional investors.

Fulcrum Therapeutics Trading Down 0.7 %

Shares of Fulcrum Therapeutics stock opened at $3.01 on Wednesday. Fulcrum Therapeutics has a 12-month low of $2.86 and a 12-month high of $13.70. The company has a market cap of $162.36 million, a price-to-earnings ratio of -9.71 and a beta of 2.24. The company’s 50-day moving average price is $3.53 and its 200-day moving average price is $6.40.

Fulcrum Therapeutics Company Profile

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.